Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
33.86
+0.06 (0.18%)
Oct 8, 2025, 11:57 AM EDT - Market open
Vor Biopharma Employees
Vor Biopharma had 159 employees as of December 31, 2024. The number of employees decreased by 9 or -5.36% compared to the previous year.
Employees
159
Change (1Y)
-9
Growth (1Y)
-5.36%
Revenue / Employee
n/a
Profits / Employee
-$10,468,088
Market Cap
232.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Dec 31, 2020 | 88 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VOR News
- 4 days ago - Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025 - GlobeNewsWire
- 13 days ago - Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha
- 15 days ago - Vor Bio Appoints Navid Z. Khan, Ph.D. - GlobeNewsWire
- 20 days ago - Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting - PRNewsWire
- 20 days ago - Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM - GlobeNewsWire
- 25 days ago - Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 5 weeks ago - Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel - GlobeNewsWire